Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Other Non-Current Assets: 2021-2024

  • China SXT Pharmaceuticals' Other Non-Current Assets was N/A to $8.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $8.5 million, marking a year-over-year change of. This contributed to the annual value of $8.3 million for FY2024, which is 4.88% down from last year.
  • According to the latest figures from Q3 2024, China SXT Pharmaceuticals' Other Non-Current Assets is $8.5 million, which was up 2.89% from $8.3 million recorded in Q1 2024.
  • China SXT Pharmaceuticals' 5-year Other Non-Current Assets high stood at $9.5 million for Q1 2022, and its period low was $8.3 million during Q1 2024.
  • Its 3-year average for Other Non-Current Assets is $8.7 million, with a median of $8.5 million in 2024.
  • Data for China SXT Pharmaceuticals' Other Non-Current Assets shows a peak YoY increase of 3.35% (in 2022) and a maximum YoY decrease of 9.42% (in 2022) over the last 5 years.
  • Over the past 4 years, China SXT Pharmaceuticals' Other Non-Current Assets (Quarterly) stood at $9.3 million in 2021, then fell by 9.42% to $8.4 million in 2022, then decreased by 7.69% to $8.7 million in 2023, then decreased by 4.88% to $8.5 million in 2024.
  • Its last three reported values are $8.5 million in Q3 2024, $8.3 million for Q1 2024, and $8.7 million during Q1 2023.